CliffBio
small molecule

EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameEMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE
Active ingredientEMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
Strength200MG;EQ 25MG BASE;EQ 25MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2026
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.